- Home
- DECK vs BIIB Comparison
DECK vs BIIB Comparison
Compare DECK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DECK
- BIIB
- Stock Information
- Founded
- DECK 1973
- BIIB 1978
- Country
- DECK United States
- BIIB United States
- Employees
- DECK N/A
- BIIB N/A
- Industry
- DECK Shoe Manufacturing
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- DECK Consumer Discretionary
- BIIB Health Care
- Exchange
- DECK Nasdaq
- BIIB Nasdaq
- Market Cap
- DECK 14.1B
- BIIB 18.7B
- IPO Year
- DECK 1993
- BIIB 1991
- Fundamental
- Price
- DECK $83.58
- BIIB $164.59
- Analyst Decision
- DECK Buy
- BIIB Buy
- Analyst Count
- DECK 21
- BIIB 24
- Target Price
- DECK $122.16
- BIIB $174.62
- AVG Volume (30 Days)
- DECK 5.7M
- BIIB 1.6M
- Earning Date
- DECK 10-23-2025
- BIIB 10-30-2025
- Dividend Yield
- DECK N/A
- BIIB N/A
- EPS Growth
- DECK 18.83
- BIIB N/A
- EPS
- DECK 6.75
- BIIB 10.97
- Revenue
- DECK $5,244,323,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- DECK $9.84
- BIIB $2.97
- Revenue Next Year
- DECK $7.36
- BIIB N/A
- P/E Ratio
- DECK $12.50
- BIIB $14.72
- Revenue Growth
- DECK 12.62
- BIIB 4.77
- 52 Week Low
- DECK $78.91
- BIIB $110.04
- 52 Week High
- DECK $223.98
- BIIB $175.86
- Technical
- Relative Strength Index (RSI)
- DECK 39.82
- BIIB 72.25
- Support Level
- DECK $79.07
- BIIB $151.83
- Resistance Level
- DECK $86.69
- BIIB $157.79
- Average True Range (ATR)
- DECK 2.80
- BIIB 5.37
- MACD
- DECK 0.55
- BIIB 1.13
- Stochastic Oscillator
- DECK 39.14
- BIIB 89.96
About DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and about 180 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.